Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors-Reference-Cited by-同舟云学术

Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors

Published:2020-04 Issue:4 Volume:15 Page:556-567
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Wang Zhijie,Duan Jianchun,Wang Guoqiang,Zhao Jing,Xu Jiachen,Han Jiefei,Zhao Zhengyi,Zhao Jun,Zhu Bo,Zhuo Minglei,Sun Jianguo,Bai Hua,Wan Rui,Wang Xin,Fei Kailun,Wang Shuhang,Zhao Xiaochen,Zhang Yuzi,Huang Mengli,Huang Depei,Qi Chuang,Gao Chan,Bai Yuezong,Dong Hua,Xiong Lei,Tian Yanhua,Wang Di,Xu Chunwei,Wang Wenxian,Li Junling,Hu Xingsheng,Cai Shangli,Wang Jie

Funder

National Natural Science Foundation of China

Beijing Municipal Natural Science Foundation

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Tumor mutational load predicts survival after immunotherapy across multiple cancer types;Samstein;Nat Genet,2019

2. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database;Singal;JAMA,2019

3. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer;Rizvi;Science,2015

4. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden;Hellmann;N Engl J Med,2018

5. First-line nivolumab in Stage IV or recurrent non-small-cell lung cancer;Carbone;N Engl J Med,2017

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

2. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer;Cancer Cell;2024-09

3. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer;Med;2024-08

4. Cell-Free DNA as a Biomarker at Diagnosis and Follow-Up in 256 B and T-Cell Lymphomas;Cancers;2024-01-11

5. Role of biomarkers in assessing response to immune checkpoint inhibitors in cancer treatment;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024